Calcitonin gene–related peptide enhances the recovery of contractile function in stunned myocardium  by Atkins, B.Zane et al.
Early myocardial reperfusion is a primary goal intreating acute myocardial ischemia and is common- place with thrombolytic therapy, percutaneous translu-minal coronary angioplasty (PTCA), and coronary
artery bypass procedures. However, early reperfusion
is complicated by myocardial stunning or reversible
dysfunction.1,2 Myocardial stunning is encountered
after most cardiac operations, cardiac transplantation,
and cardiopulmonary arrest and after less clinically
obvious episodes of reversible myocardial ischemia.1
However, consequences of stunned myocardium are
often prevented by vasoactive medications. Still, it is
proposed that prevention of myocardial stunning may
improve the clinical course after reversible myocardial
ischemia. To date, few therapies are proved to augment
the recovery of myocardial performance within
stunned myocardium without the induction of deleteri-
ous effects.3
Introduction: Calcitonin gene-related peptide, a potent vasodilating inotrop-
ic agent, increases coronary artery perfusion when administered exogenous-
ly and reduces ischemic injury in nonmyocardial tissue. However, it is
unclear whether this agent improves recovery of myocardial performance
after reversible myocardial ischemia.
Methods: Nine dogs underwent complete occlusion of the left anterior
descending coronary artery for 15 minutes and were monitored during 24
hours of reperfusion. Calcitonin gene–related peptide (0.07 µg · kg–1 ·
min–1), nitroglycerin (65 µg · kg–1 · min–1), or saline solution placebo was
infused intravenously during initial reperfusion. Ischemia/reperfusion was
repeated in concurrent 24-hour periods until all animals received infusions in
random order. Micromanometry and sonomicrometry determined left ven-
tricular pressure and myocardial segment length. Myocardial performance,
based on the linear relationship between stroke work and end-diastolic seg-
ment length, was estimated with the preload recruitable work area. Results
were analyzed as percent control and compared statistically with the use of
repeated measures analysis of variance.
Results: Recovery of myocardial performance was augmented during reper-
fusion with calcitonin gene–related peptide infusion relative to placebo (P =
.005; mean preload recruitable work area ± SE after calcitonin gene–related
peptide infusion, 2484 ± 705 mm Hg at 90 minutes of reperfusion versus
1473 ± 300 mm Hg for placebo. Recovery of performance after nitroglycerin
infusion was similar to recovery after placebo.
Conclusions: Calcitonin gene–related peptide infusion improves recovery of
contractile function in stunned myocardium. Unlike inotropic agents that
impair recovery from reversible ischemia, calcitonin gene–related peptide
may confer cardioprotective effects on ischemic myocardium. (J Thorac
Cardiovasc Surg 2000;119:1246-54)
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Calcitonin gene–related peptide (CGRP) is a
vasoactive protein found in cardiac slow-conducting
c-fiber afferents, and CGRP receptors are widely dis-
tributed throughout the myocardium and vascular sys-
tem.4 Functionally, CGRP is a potent endogenous
vasodilator and exerts chronotropic and inotropic
effects directly on the myocardium.5,6 Because of
these vasodilatory properties, elevated concentrations
of CGRP that are observed in regional tissue and in
plasma after transient myocardial ischemia could have
beneficial effects.7-9
Recognizing these unique properties, investigators
have recently evaluated exogenous CGRP in
ischemia. For instance, CGRP administration may
improve tissue viability and functional recovery in
ischemic skeletal muscle.10-12 In addition, CGRP
administration delayed the onset of ischemia in
patients with coronary artery disease who were sub-
jected to exercise treadmill testing.13 Despite these
findings, few data describe the effect of exogenous
CGRP administration on indices of myocardial per-
formance after reversible myocardial ischemia.
Therefore, this study was undertaken to assess the
ability of CGRP to augment recovery of contractile
function within stunned myocardium in a canine
model of regional myocardial ischemia.
Methods
Experimental preparation.  All experiments were con-
ducted in accordance with guidelines published in the “Guide
for the Care and Use of Laboratory Animals” (NIH
Publication No. 86-23, revised 1985) and under protocols
approved by Duke University. Nine dogs (20-25 kg) were
premedicated with pentobarbital sodium (25 mg/kg, intra-
venously) and fentanyl citrate (10-20 µg/kg, intravenously),
intubated, and mechanically ventilated (Puritan-Bennett
Corp, Medical Products Division, Los Angeles, Calif). A ster-
ile thoracotomy in the fifth left intercostal space exposed the
heart, and pneumatic occluders were secured around the
superior and inferior venae cavae. After pericardiotomy, a sil-
icone rubber pneumatic occluder was placed around the left
anterior descending (LAD) coronary artery distal to the first
diagonal branch. A brief test occlusion identified the myocar-
dial region rendered ischemic (Fig 1). One pair of piezoelec-
tric dimension transducers was implanted intramyocardially
in the ischemic left ventricular (LV) region. A second pair of
dimension transducers was placed in the distribution of the
left circumflex (LCX) coronary artery to assess nonischemic
myocardium (Fig 1). Silicone rubber catheters were implant-
ed in left atrium and pleural space to allow subsequent place-
ment of pressure transducers in these spaces. Implanted hard-
ware were brought through a separate rib space and through
a silicone rubber skin appliance positioned dorsal to the tho-
racotomy incision. The thoracotomy was closed in layers, and
animals were allowed to recover for 2 weeks.
Data acquisition. Each dog was studied in the conscious
state after mild sedation (morphine sulfate, 0.7-1.0 mg/kg,
intramuscularly). Dimension transducer pairs were coupled
to a sonomicrometer with a sampling rate of 250 Hz and a
frequency response up to 50 Hz. Micromanometers (model
PC-500; Millar Instruments, Inc, Houston, Tex) were posi-
tioned in the LV cavity and pleural space with implanted sil-
icone rubber catheters.
Intravenous heparin sodium (300 units/kg) and lidocaine
(2 mg/kg) were administered, and baseline physiologic
data were recorded. The pneumatic LAD coronary artery
occluder was fully inflated for 15 minutes, and standard
electrocardiogram leads and myocardial segment lengths
were monitored to verify myocardial ischemia. Animals
were observed during 45 minutes of reperfusion, after
which each animal received intravenous CGRP (0.07 µg ·
kg–1 · min–1; Peninsula Laboratory, San Jose, Calif), nitro-
glycerin (65 µg · kg–1 · min–1), or saline solution placebo
infusion for 1 hour. Data were collected at steady state and
across altered loading conditions produced by vena caval
occlusion at baseline, during acute ischemia, and after 1.5,
3, 8, and 24 hours of reperfusion. The initial data collection
during drug infusion was begun at 1.5 hours of reperfusion
to allow 30 minutes of drug infusion to achieve steady state
conditions.
Fig 1. Experimental preparation shows the pneumatic occlud-
er secured around the LAD coronary artery (A), left atrial
introducer catheter (B), intramyocardial ultrasonic dimension
transducer pair in the ischemic (darkened area) LAD coro-
nary artery region (C), and ultrasonic dimension transducer
pair in the LCX coronary artery distribution (D). Implanted
pleural catheters and vena caval pneumatic occluders are not
shown.
After 24 hours of recovery from ischemia, baseline condi-
tions were confirmed before repeated ischemia was induced.
This model has been repeatedly validated as one of reliable
recovery from reversible myocardial ischemia.14-16 Infusion
sequence after ischemia was formally randomized such that
all 9 animals underwent 3 occlusions and received all 3 infu-
sions during 3 concurrent 24-hour periods. By this method,
each animal had a 1-in-3 chance of receiving 1 of 3 infusion
sequences.
At study completion, animals were killed according to
Duke University guidelines, and autopsies documented cor-
rect positioning of implanted hardware. The LV was serially
sectioned at 1-cm intervals to ensure that no animals experi-
enced gross myocardial infarction.
Data analysis. Analog data were filtered, digitized in real
time by an analog-to-digital converter (ADAC 1012; ADAC
Laboratories, Woburn, Mass), and collected on a personal
computer–based system. Data analysis was performed on a
VAXStation model 4000 (Digital Equipment Corp, Maynard,
Mass).
The first-time derivative of LV transmural pressure was
computed from the digital pressure waveform as a running 5-
point polyorthogonal transformation. The cardiac cycle was
defined automatically on the basis of the first-time derivative
of LV transmural pressure, as described previously.14
Regional stroke work (SW) analog was calculated as the
integral of LV transmural pressure (P) and myocardial seg-
ment length (L) through each cardiac cycle15,16:
SW = ∫ P d L (Eq 1)
where d is derivative. SW was regressed against end-diastolic
segment length (L
ed) to obtain the linear preload recruitable
stroke work (PRSW) relationship described by the following
equation:15,16
SW = M
w
(L
ed – Lw) (Eq 2)
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where M
w 
and L
w
are the slope and x-intercept of the rela-
tionship, respectively.
Because reversible myocardial ischemia simultaneously
alters M
w
and L
w
, accurate assessment of contractile function
with the use of the PRSW relationship alone is difficult.
Therefore, contractile performance was quantified with the
use of the preload recruitable work area (PRWA), a normal-
ized index of regional contractile performance. The PRWA
incorporates changes in M
w
and L
w
and represents contractile
function as one analyzable variable. PRWA was defined by
the area beneath the line described by the PRSW relationship
and determined as follows:
PRWA = (M
w
/2) ([1.2] [L
wmax
] – [L
w
])2 (Eq 3)
L
wmax
is the maximal x-intercept obtained throughout the
study of a given animal. The factor of 1.2 was included to
ensure that PRWA was always positive, yet diminished sig-
nificantly as L
w 
approached L
wmax
.
15,16
Hemodynamic variables, PRSW relationships, and PRWA
were determined for baseline, acute ischemia, and 1.5, 3, 8,
and 24 hours of reperfusion after placebo, CGRP, or nitro-
glycerin infusions.
Statistics. Steady state data represent mean values over 10
to 20 cardiac cycles. Analysis of variance for repeated mea-
sured was used to detect the effects of time, treatment
sequence, or treatment type (placebo, nitroglycerin, or
CGRP) on hemodynamic parameters and PRWA. For analy-
sis of variance with PRWA, analysis was performed on data
after treatment was started (1.5, 3, 8, and 24 hours of reper-
fusion). Analysis of covariance used the baseline value of
PRWA before ischemia to control for the significant differ-
ences in baseline values because of different intercrystal dis-
tances between animals and because of differences in
sonomicrometer tracking between occlusions. Unless other-
wise stated, all data are mean ± SD.
Results
Nine animals underwent 3 concurrent episodes of
reversible myocardial ischemia and received 1 of 3
infusions after each ischemic period. Three animals did
not complete reperfusion from the third occlusion
because of hardware malfunction (n = 2 animals) or
cardiac arrhythmia (n = 1 animal). Unless otherwise
stated, data are presented for the 6 animals that com-
pleted 3 studies each.
After LAD coronary artery occlusion and the onset
of regional myocardial ischemia, systolic shortening
within the ischemic region decreased immediately,
worsened to systolic bulging, and slowly normalized
during the 24 hours of recovery, as evidenced by the
change in segment lengths and depicted in Fig 2.
The deterioration in systolic shortening was manifest
by the narrowing of the pressure-segment length work
loops created in the ischemic LAD coronary artery
region (Fig 2). As expected, systolic shortening in the
Fig 2. Representative raw data derived from the LAD coro-
nary artery and the LCX myocardial regions are shown for
one animal. Segment lengths and LV transmural pressure-
segment length work loops in the respective distributions dur-
ing control conditions, acute ischemia, and after 1.5, 3, 8, and
24 hours of reperfusion document the regional ischemia and
gradual recovery within the LAD coronary artery region.
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LCX coronary artery region was unaffected by LAD
coronary artery occlusion, and pressure-segment
length work loops from the LCX coronary artery
region were unchanged after ischemia (Fig 2). These
changes in raw data were seen regardless of the infu-
sion used during reperfusion.
Hemodynamic variables including heart rate, mean
ejection pressure, LV end-diastolic pressure, and end-
diastolic segment lengths were compared during
ischemia and reperfusion in the presence of CGRP,
nitroglycerin, or placebo (Fig 3). Compared with
placebo, CGRP infusion was associated with
increased heart rate during infusion (P < .0001) and
after 8 hours of reperfusion (P = .04; Fig 3, A).
Conversely, nitroglycerin infusion did not signifi-
cantly alter heart rate at any point that was measured
during ischemia and reperfusion (P > .1 for all time
points; Fig 3, A). Both CGRP and nitroglycerin infu-
sions decreased LV end-diastolic pressure (Fig 3, B;
CGRP, P = .003; nitroglycerin, P = .002) and mean
ejection pressure (Fig 3, C; CGRP, P = .01; nitro-
glycerin, P = .001) relative to placebo, but these
effects were seen during infusion only. Alteration and
recovery of end-diastolic segment length were simi-
lar after CGRP and nitroglycerin infusions relative to
placebo, which implied that discrete changes in
regional geometry were similar after each infusion (P
> .3 for all time points; Fig 3, D).
Construction of PRSW relationships between region-
al stroke work and end-diastolic segment length during
ischemia and reperfusion yielded highly linear relation-
ships (r2 > 0.90; P = .001) in each animal. After tran-
sient regional ischemia, PRSW relationships were typ-
ically characterized by an initial decrement in the M
w
and an increase in L
w
, regardless of the infusion used
during recovery (data not shown). Effects of ischemia
on M
w
and L
w
were maximal during acute ischemia and
returned toward baseline as reperfusion continued.
Similar alterations in M
w
and L
w
were seen after
regional ischemia, irrespective of the infusion used dur-
ing recovery. Consequently, the order of infusion did
not affect PRWA values that were obtained (P > .2).
After CGRP infusion, PRWA in the ischemic LAD
coronary artery region was significantly increased at
each time point of reperfusion relative to placebo and
nitroglycerin (P = .01, by analysis of covariance),
although the raw value of PRWA was greater for CGRP
than placebo only at 1.5 hours of reperfusion because
of large but insignificant differences in baseline PRWA
between treatment groups (Fig 4). To correct for differ-
ences in baseline PRWA between treatments, PRWA
was also calculated as percent of baseline values (Fig
5). Here the effect of CGRP throughout subsequent
reperfusion (detected by analysis of covariance but not
visualized in Fig 4) was better detected and visualized
throughout subsequent reperfusion (P = .01) and for
each time point (P < .05 for 1.5, 3, 8, and 24 hours; Fig
5). Nitroglycerin had no significant effect on PRWA at
any time during reperfusion (Figs 4 and 5). Given no
effect of nitroglycerin on PRWA, analysis of covari-
ance was repeated on raw PRWA data for all 8 animals
that received complete courses of placebo and CGRP
(Fig 6). Here, the effect of CGRP relative to placebo
was highly significant throughout subsequent reperfu-
sion (P = .005) and for each individual time point (P <
.05; Fig 6).
In the nonischemic LCX coronary artery region,
CGRP did not significantly affect PRWA values rela-
tive to placebo throughout reperfusion (Fig 7).
Discussion 
Increased understanding of the mechanisms and
manifestations of acute coronary syndromes and
improvements in managing these syndromes has intro-
duced myocardial stunning as an important issue of
cardiac care.1,3 Common clinical scenarios in which
postischemic dysfunction may be encountered include
reperfusion after successful PTCA or thrombolytic
therapy; after coronary artery bypass grafting, heart
transplantation, or other cardiac procedures; and after
successful resuscitation from cardiopulmonary
arrest.1,3
Patients with hemodynamically significant stunning
are typically managed with inotropic therapy, which
mitigates the functional detriment caused by reversible
ischemia until the heart has functionally recovered.
However, widespread use of inotropic or vasoactive
medications may not always be beneficial because
inotropic agents increase myocardial oxygen consump-
tion, increase the risk of arrhythmias, thereby necessi-
tating invasive hemodynamic monitoring, and thus may
adversely affect the long-term function of stunned
myocardium.1,15 Therefore, a strategy to augment the
performance of stunned myocardium without the sub-
sequent induction of negative functional consequences
is attractive and has ready clinical application.
CGRP is an endogenous peptide that exerts
chronotropic, inotropic, and vasodilatory properties
directly on the myocardium. The role of CGRP in
myocardial ischemia has been intensely investigat-
ed.5,6,17-19 In fact, plasma levels of CGRP are increased
in patients with acute myocardial ischemia,7 and
Lechleitner and colleagues9 have recently noted
increased endogenous CGRP during coronary artery
bypass procedures that are performed without car-
diopulmonary bypass. Furthermore, Li and col-
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leagues20 have reported that isolated rat hearts precon-
ditioned with CGRP have preserved function after
ischemia and that preconditioning with CGRP appears
to electrically stabilize the myocardium during subse-
quent ischemia.
However, few reports of exogenous CGRP adminis-
tration in myocardial ischemia exist. Uren and col-
leagues13 infused CGRP in patients with coronary
artery disease who underwent exercise treadmill testing
and found that CGRP administration was associated
with delayed onset of ischemia. In addition, Källner,
Gonon, and Franco-Cereceda21 noted that CGRP infu-
sion after regional myocardial ischemia augmented
postischemic coronary artery flow in pigs. Although
encouraging, previous investigation of CGRP in
myocardial ischemia has lacked assessment of contrac-
tile function. The current study represents the first
known load-insensitive determination of contractile
function after exogenous CGRP infusion in a closed-
chest, conscious model of stunned myocardium.
In the current study, contractile function was
assessed by means of the PRWA, a normalized index of
regional myocardial performance. PRWA is especially
useful when serial assessment of regional contractile
performance is desired. For example, during episodes
of ischemia and reperfusion, simultaneous alterations
in the slope and x-intercept of the PRSW relationship
preclude accurate statements of performance based on
the PRSW relationship alone. However, PRWA incor-
porates both the PRSW slope and x-intercept to sum-
marize assessment of contractile function.14,15 In this
study, relative to placebo, brief treatment with CGRP
significantly improved contractile function (PRWA) in
the ischemically injured zone throughout reperfusion
(Figs 4, 5, and 6). This effect persisted up to 24 hours
of reperfusion in the ischemically injured LAD coro-
Fig 3. Mean heart rate (A) and LV end-diastolic pressure (B) for placebo, CGRP, and nitroglycerin (NTG) during
control conditions, acute ischemia, and 1.5, 3, 8, and 24 hours of reperfusion. NS, Not significant.
A
B
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nary artery zone (Figs 5 and 6), despite the absence of
significant residual direct effect of CGRP on contractile
function in the uninjured LCX zone after the CGRP
infusion was stopped (Fig 7).
These results are important and unique because pre-
vious studies have not examined the recovery of func-
tion after myocardial ischemia. Several inotropic
agents have been evaluated in the general context of
myocardial ischemia, yet few data examine the long-
term (>1 hour) effects of inotropic stimulation of hearts
during ischemia and reperfusion. Kabas and col-
leagues15 evaluated conscious dogs after 15 minutes of
regional myocardial ischemia followed by reperfusion
with either dopamine or saline solution placebo infu-
sion. Myocardial performance was significantly aug-
mented during dopamine infusion; however, cate-
cholamine stimulation of injured myocardium resulted
in significantly depressed performance throughout the
22 additional hours of reperfusion. The authors con-
cluded that inotropic stimulation of injured myocardi-
um might interfere with its functional recovery.
However, similar findings have not been reproduced
clinically, and it is not apparent whether these findings
are clinically important. Nevertheless, the current study
opposes previously held notions based on the study of
Kabas and colleagues that inotropic stimulation of
stunned myocardium might ultimately be deleterious.
Several points about the data of the current study are
important. For instance, CGRP was associated with
increased heart rate during infusion and after 8 hours of
reperfusion relative to placebo. However, the
chronotropic effects of CGRP do not minimize the
importance of the functional results that were reported
because PRWA is entirely based on the PRSW rela-
tionship. For instance, the PRSW relationship has been
repeatedly shown to be independent of heart rate varia-
Fig 3. Cont’d. Mean ejection pressure (C) and end-diastolic segment length (D) for placebo, CGRP, and nitroglyc-
erin (NTG) during control conditions, acute ischemia, and 1.5, 3, 8, and 24 hours of reperfusion. NS, Not significant.
C
D
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tions across a wide physiologic range.14 In addition, the
absolute value of heart rate increase with CGRP was
relatively small (<20%), and this degree of increase is
not unusual because CGRP is known to exert
chronotropic effects on the myocardium.4,17,19 Still, the
long-term effects of CGRP’s increased chronotropy on
stunned myocardium are uncertain.
Similarly, given the well-described pharmacologic
properties of CGRP, the increased PRWA noted in the
nonischemic circumflex region is not surprising, and
the return of PRWA to baseline levels after comple-
tion of the CGRP infusion is consistent with the
reported normal half-life of this agent.22 This finding
further suggests that CGRP may confer protective
properties on ischemic myocardium relative to nor-
mal heart.
The current study was designed to evaluate recovery of
myocardial performance after CGRP infusion and cannot
offer definitive statements about the molecular mecha-
nisms whereby contractile function is benefited.
However, several plausible mechanisms exist by which
CGRP may augment performance within stunned
myocardium. Depressed contractility within stunned
myocardium is often attributed to altered intracellular
calcium homeostasis, and evidence suggests that
reversible myocardial ischemia impairs the normally sen-
sitive interactions between the contractile apparatus and
intracellular calcium.1,3,23,24 Curiously, CGRP appears to
Fig 5. PRWA data (n = 6; mean ± SD) expressed as percent baseline from the ischemic LAD coronary artery region
after CGRP or nitroglycerin (NTG) infusion compared with placebo. After reversible myocardial ischemia, PRWA
was significantly enhanced by CGRP over all reperfusion (P = .01) and at each time in reperfusion (P < .05).
Nitroglycerin did not significantly affect PRWA compared with placebo.
Fig 4. PRWA data (n = 6; mean ± SD) from the ischemic LAD coronary artery region after CGRP or nitroglycerin
(NTG) infusion compared with placebo. After reversible myocardial ischemia, contractile performance (PRWA)
was significantly enhanced by CGRP over all reperfusion (P = .01) and after 1.5 hours of reperfusion (P = .04).
Conversely, nitroglycerin did not significantly alter PRWA compared with placebo.
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affect intracellular calcium balance through activation of
the second messenger, protein kinase C.25,26 Protein
kinase C plays an important role in ischemic precondi-
tioning and may influence intracellular calcium home-
ostasis by a number of mechanisms, including activity at
the sarcoplasmic reticulum Ca2+ pump or by altering the
contractile apparatus to increase Ca2+ sensitivity.27,28 By
activating a second messenger (such as protein kinase C),
CGRP could induce prolonged, enhanced effects such as
those seen in the present study, despite the protein’s rela-
tively short half-life.22 Finally, CGRP may also benefit
ischemically injured myocardium as a simple vasodilator.
Although vasodilation with nitroglycerin did not dupli-
cate the benefits of CGRP, at least one previous study has
observed beneficial effects of vasodilators (dipyridamole
and papaverine) not achieved with nitroglycerin in a sim-
ilar model.29
In summary, the administration of CGRP after
reversible myocardial ischemia was associated with
enhanced recovery of contractile performance within
the ischemic region and appears to mitigate the pro-
longed decrement in contractility typical of stunned
myocardium. Given the increased incidence of patients
experiencing reversible myocardial ischemia as a result
of PTCA, thrombolytic therapy, and surgical revascu-
larization, the potential application of these techniques
is far-reaching and may represent an alternative to stan-
dard inotropic therapy in these settings.
Fig 7. PRWA data (mean ± SD) from the nonischemic LCX coronary artery region after CGRP infusion compared
with placebo. PRWA was increased during CGRP infusion; however, PRWA for CGRP and placebo were similar
during the remainder of recovery.
Fig 6. PRWA data (mean ± SD) in the ischemic LAD coronary artery region for all 8 animals that received CGRP
infusion compared with placebo. After reversible ischemia, contractile performance (PRWA) was significantly
enhanced by CGRP over all reperfusion (P = .005) and at each time in reperfusion (P < .05).
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